Production (Stage)
ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -100.00% |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | -16.40% | -0.60% | 4.02% | 2.84% | -4.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.40% | -53.92% | -45.91% | -37.70% | -18.50% |
| Operating Income | 60.40% | 24.42% | 12.51% | -2.70% | -45.25% |
| Income Before Tax | 54.67% | 17.51% | 5.81% | -6.25% | -53.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.67% | 17.51% | 5.81% | -6.25% | -53.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.67% | 17.51% | 5.81% | -6.25% | -53.89% |
| EBIT | 60.40% | 24.42% | 12.51% | -2.70% | -45.25% |
| EBITDA | 61.78% | 24.53% | 12.71% | -2.86% | -46.66% |
| EPS Basic | 61.05% | 23.53% | 24.86% | 24.39% | 14.40% |
| Normalized Basic EPS | 64.09% | 27.70% | 27.92% | 24.15% | 14.76% |
| EPS Diluted | 61.05% | 24.42% | 25.53% | 25.00% | 15.01% |
| Normalized Diluted EPS | 64.09% | 28.32% | 28.40% | 24.60% | 15.19% |
| Average Basic Shares Outstanding | 17.87% | 23.65% | 30.61% | 44.69% | 66.72% |
| Average Diluted Shares Outstanding | 17.87% | 22.41% | 29.15% | 42.88% | 64.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |